Aligos rises on receiving upfront payment from hepatitis B drug license deal
06/07/2026 21:19
BUZZ-Aligos rises on receiving upfront payment from hepatitis B drug license deal ** Shares of biotech firm Aligos Therapeutics ALGS.O jump 23.1% to $7.2O after the bell
** ALGS says has received upfront payment of $25 mln from exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech 688278.SS
** Under terms, ALGS is also eligible to receive up to $420 mln in clinical, regulatory and sales milestones
** Pevifoscorvir sodium is ALGS' experimental hepatitis B drug, designed to block the virus and reduce disease markers
** Pevifoscorvir sodium was granted Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration
** ALGS has fallen 36.1% YTD
(Reporting by Juby Babu in Mexico City)
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue